Learn about AFCR’s support for the development and conversion of exciting laboratory breakthroughs into new and more effective cancer treatments, screenings and preventive technologies. Listed in this section are Translational Research initiatives which are or have been sponsored by AFCR, made possible with our dedicated donors’ support.
First-in-class New Immunotherapy for Gastrointestinal Cancers
Overview Innovation: Targeting Immune Engagement Targeted Cancer(s): Gastrointestinal cancers, including pancreas, stomach, liver and bowel. Current Stage: Set to initiate a clinical study of our first-in-class bispecific GI Cancer targeting/T-cell…
YIV-906: Therapeutics—first-in-class botanical cancer platform drug
Ongoing since 2020 Company Overview Innovation: Therapeutics—first-in-class botanical cancer platform drug Targeted Cancer(s): Liver cancer Scientific Leadership: Yung-Chi Cheng, Ph.D.; Shwu-Huey Liu, Ph.D. Stage of Project: Phase II clinical trial about to commence; orphan…
Multi-functional antibodies to target cancer on multiple fronts
Advanced cancers typically suppress the immune response by multiple mechanisms. By carefully engineering multi-functional antibody therapies, there is the potential for more effective treatment.
Determining the Risk of Hereditary Breast and Ovarian Cancer (HBOC) in China
Understanding the risk of breast cancer in the Chinese population is very important due to the exponential increase in incidence...
Gastric Cancer Research
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death worldwide.
